DUBLIN , Feb. 22, 2016 /CNW/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP) (ENL.TO), today announced the availability of BELBUCA™ (buprenorphine) buccal film, the first ...
More Than 115 Million Lives Now Have Preferred Access To BELBUCA In The U.S. RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing ...
New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility Endo Pharmaceuticals Inc., a subsidiary ...
--BioDelivery Sciences International, Inc., a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today presented at the American ...
"These posters include important scientific data for healthcare professionals to consider concerning the safety profile of buprenorphine buccal film and oxycodone," said Thomas Smith, MD, Chief ...
RALEIGH, N.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic ...
Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C., Jan. 15, 2021 (GLOBE NEWSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results